This review systematically summarizes the core regulatory networks of ferroptosis in prostate cancer (such as the PI3K-AKT-mTOR, Hippo/YAP, PGE2, and their downstream pathways), summarizes combination treatment strategies and clinical trial progress, proposes a three-pronged translational framework of "ferroptosis regulatory network-biomarkers-precision therapy", and discusses the challenges it faces in terms of drug resistance, targeting accuracy, and clinical translation. The gene discussed is MTOR; the disease is prostate carcinoma.